|SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549
|----------------------------------------------------------



|FORM 8-K
|--------



|CURRENT REPORT
|--------------



|Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
|----------------------------------------------------------------------



|Date of Report (Date of earliest event reported): | May 13, 2003
|------------------------------------------------- | ------------



|Introgen Therapeutics, Inc.
      (Exact name of registrant as specified in its charter)
|----------------------------------------------------------------------------------------

|Delaware
      (State or other jurisdiction
      of incorporation) | 0-21291
      (Commission
      File Number) | 74-2704230
      (IRS Employer
      Identification No.)
|------------------------------------------------------------------- | -------------------------------------------- | --------------------------------------------------------



|301 Congress Avenue, Suite 1850, Austin, Texas
      78701
      (Address of principal executive offices) (Zip Code)
|--------------------------------------------------------------------------------------------------------------------

|Registrants telephone number, including
      area code: | (512) 708-9310
|--------------------------------------------------------- | --------------





|(Former name or former address, if changed since last report)
|-------------------------------------------------------------



| |  | 
| |  | 



---





|Item 7.  Financial Statements and Exhibits.
|-------------------------------------------



|(c)  Exhibits.
|--------------



|99.1  Press
Release dated May 13, 2003.
|---------------------------------------



|Item 9.  Regulation FD Disclosure.
|----------------------------------



|The press release filed as
        an exhibit to this report is being furnished under Item 12 (Furnishing
        of Earnings Releases) as contemplated by SEC Release Nos. 33-8176 and
        33-8216.
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|SIGNATURES
|----------



|Pursuant to the
requirements of the Securities  Exchange Act of 1934, the registrant has duly caused this
report to be signed  on its behalf by the undersigned hereunto duly authorized.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Dated: May 13, 2003 | INTROGEN THERAPEUTICS, INC                          
|------------------- | ----------------------------------------------------
|                    |                                                     
|                    | James W. Albrecht, Jr.
      Chief Financial Officer



| | -2- | 
| | --- | 



---





|INDEX TO EXHIBITS
|-----------------



|Exhibit
      Number | Description of Document          
|-------------------- | ---------------------------------
|                     |                                  
|99.1                 | Press Release dated May 13, 2003.







---